177Lu-DOTATATE in patients with well-differentiated, high-grade NETs

Nitya Raj, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the role of peptide receptor radionuclide therapy (PRRT) in the treatment of neuroendocrine tumors (NETs). Prospective data has demonstrated 177Lu-DOTATATE to be especially effective in well-differentiated, high-grade NETs and further research will determine if moving PRRT into earlier lines of therapy will optimize outcomes. This interview took place virtually at the 2022 Great Debates & Updates in Gastrointestinal Malignancies Congress.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.